Unione Europea - danese - EMA (European Medicines Agency)

diurnal europe b.v. - hydrocortison - adrenal hyperplasia, congenital - kortikosteroider til systemisk brug - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.

Unione Europea - danese - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochlorid - multipel sklerose, recidiverende-remitterende - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1)orpatients med hurtigt udviklende alvorlige relapserende remitterende multipel sklerose, der er defineret ved 2 eller flere invaliderende tilbagefald i et år, og med 1 eller flere gadolinium øge læsioner på hjernen mr-scanning eller en betydelig stigning i t2 læsion belastning i forhold til en tidligere de seneste mr -.

Unione Europea - danese - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochlorid - multipel sklerose, recidiverende-remitterende - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Unione Europea - danese - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinom, ikke-småcellet lunge - antineoplastiske midler - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - fingolimodhydrochlorid - kapsler, hårde - 0,25 mg

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

pensa pharma ab - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

reddy holding gmbh - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

macure healthcare limited - lorazepam - tabletter - 0,5 mg